Literature DB >> 20940046

Transforming growth factor-β and the hallmarks of cancer.

Maozhen Tian1, Jason R Neil, William P Schiemann.   

Abstract

Tumorigenesis is in many respects a process of dysregulated cellular evolution that drives malignant cells to acquire six phenotypic hallmarks of cancer, including their ability to proliferate and replicate autonomously, to resist cytostatic and apoptotic signals, and to induce tissue invasion, metastasis, and angiogenesis. Transforming growth factor-β (TGF-β) is a potent pleiotropic cytokine that functions as a formidable barrier to the development of cancer hallmarks in normal cells and tissues. Paradoxically, tumorigenesis counteracts the tumor suppressing activities of TGF-β, thus enabling TGF-β to stimulate cancer invasion and metastasis. Fundamental gaps exist in our knowledge of how malignant cells overcome the cytostatic actions of TGF-β, and of how TGF-β stimulates the acquisition of cancer hallmarks by developing and progressing human cancers. Here we review the molecular and cellular mechanisms that underlie the ability of TGF-β to mediate tumor suppression in normal cells, and conversely, to facilitate cancer progression and disease dissemination in malignant cells.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940046      PMCID: PMC3076078          DOI: 10.1016/j.cellsig.2010.10.015

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  274 in total

1.  PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling.

Authors:  Xia Lin; Xueyan Duan; Yao-Yun Liang; Ying Su; Katharine H Wrighton; Jianyin Long; Min Hu; Candi M Davis; Jinrong Wang; F Charles Brunicardi; Yigong Shi; Ye-Guang Chen; Anming Meng; Xin-Hua Feng
Journal:  Cell       Date:  2006-06-02       Impact factor: 41.582

2.  Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors.

Authors:  Leilei Yang; Chunming Mao; Yan Teng; Wenlong Li; Jishuai Zhang; Xuan Cheng; Xiaobing Li; Xinghai Han; Zhaofan Xia; Hongkui Deng; Xiao Yang
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.

Authors:  Virginia G Kaklamani; Lisa Baddi; Junjian Liu; Diana Rosman; Sharbani Phukan; Ciarán Bradley; Chris Hegarty; Bree McDaniel; Alfred Rademaker; Carole Oddoux; Harry Ostrer; Loren S Michel; Helen Huang; Yu Chen; Habibul Ahsan; Kenneth Offit; Boris Pasche
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

4.  A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.

Authors:  W P Schiemann; W M Pfeifer; E Levi; M E Kadin; H F Lodish
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

5.  Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma.

Authors:  B I Dalal; P A Keown; A H Greenberg
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer.

Authors:  S M Gorsch; V A Memoli; T A Stukel; L I Gold; B A Arrick
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

7.  Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair.

Authors:  A Igarashi; H Okochi; D M Bradham; G R Grotendorst
Journal:  Mol Biol Cell       Date:  1993-06       Impact factor: 4.138

Review 8.  Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways.

Authors:  Marie-Jose Goumans; Franck Lebrin; Gudrun Valdimarsdottir
Journal:  Trends Cardiovasc Med       Date:  2003-10       Impact factor: 6.677

9.  Arkadia-Smad7-mediated positive regulation of TGF-beta signaling in a rat model of tubulointerstitial fibrosis.

Authors:  Fu-You Liu; Xiao-Zhao Li; You-Ming Peng; Hong Liu; Ying-Hong Liu
Journal:  Am J Nephrol       Date:  2007-03-07       Impact factor: 3.754

10.  Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.

Authors:  Samy Lamouille; Rik Derynck
Journal:  J Cell Biol       Date:  2007-07-23       Impact factor: 10.539

View more
  112 in total

1.  Aloe vera non-decolorized whole leaf extract-induced large intestinal tumors in F344 rats share similar molecular pathways with human sporadic colorectal tumors.

Authors:  Arun R Pandiri; Robert C Sills; Mark J Hoenerhoff; Shyamal D Peddada; Thai-Vu T Ton; Hue-Hua L Hong; Gordon P Flake; David E Malarkey; Greg R Olson; Igor P Pogribny; Nigel J Walker; Mary D Boudreau
Journal:  Toxicol Pathol       Date:  2011-09-21       Impact factor: 1.902

Review 2.  Epigenetic memories: structural marks or active circuits?

Authors:  Floriane Nicol-Benoît; Pascale Le-Goff; Yves Le-Dréan; Florence Demay; Farzad Pakdel; Gilles Flouriot; Denis Michel
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

3.  Zyxin is a transforming growth factor-β (TGF-β)/Smad3 target gene that regulates lung cancer cell motility via integrin α5β1.

Authors:  Nikica Mise; Rajkumar Savai; Haiying Yu; Johannes Schwarz; Naftali Kaminski; Oliver Eickelberg
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.157

4.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

5.  Understanding and targeting resistance to anti-angiogenic therapies.

Authors:  Jeffrey M Clarke; Herbert I Hurwitz
Journal:  J Gastrointest Oncol       Date:  2013-09

6.  Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling.

Authors:  Haijun Zhang; Fanyan Meng; Sherwin Wu; Bas Kreike; Seema Sethi; Wei Chen; Fred R Miller; Guojun Wu
Journal:  Cancer Res       Date:  2011-07-12       Impact factor: 12.701

7.  TGF-β Stimulation of EMT Programs Elicits Non-genomic ER-α Activity and Anti-estrogen Resistance in Breast Cancer Cells.

Authors:  Maozhen Tian; William P Schiemann
Journal:  J Cancer Metastasis Treat       Date:  2017-08-21

Review 8.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

9.  TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

Authors:  Tristan Courau; Djamel Nehar-Belaid; Laura Florez; Béatrice Levacher; Thomas Vazquez; Faustine Brimaud; Bertrand Bellier; David Klatzmann
Journal:  JCI Insight       Date:  2016-06-16

10.  Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling.

Authors:  Paul T Fullerton; Chad J Creighton; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.